MONTREAL, June 11, 2019 /CNW/ - Mondias Naturals
Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to
announce the results of its annual general and special meeting of
shareholders (the "Meeting"), which was held yesterday in
Montreal, Quebec. All of the
nominees listed in the Company's management information circular
dated May 6, 2019, were re-elected as
directors.
![Logo: Mondias Naturals (CNW Group/Mondias Natural Products Inc.) Logo: Mondias Naturals (CNW Group/Mondias Natural Products Inc.)](https://mma.prnewswire.com/media/900865/Mondias_Natural_Products_Inc__Mondias_announces_the_results_of_i.jpg)
"This has been a very good first six months for Mondias as a
newly listed public company," said Jean-Philippe Gravel, President and Chief
Executive Officer of Mondias. "Our proprietary CELEXT07 bio-defense
stimulant plant extract is attracting increasing interest from
large players in the agricultural, horticulture and cannabis
industries. Our consumer health products sector is also progressing
as expected, as we are preparing to launch a new line of sleeping
aids products for the second part of 2019. These initiatives, along
with others planned for later in the year, will enable Mondias to
generate growth and new opportunities in 2019."
"The Board is pleased with the results obtained to date and is
strongly committed in helping Mondias to pursue its strategic
growth plan. Our Board has the market expertise and skill set
needed to guide the Company in creating value for our
shareholders," added Mr. André Rancourt, Executive Chairman of
Mondias.
A total of 43 shareholders were represented in person or by
proxy at the Meeting, holding 42,663,175 shares, or 67.57% of
Mondias' issued and outstanding shares.
Detailed results of the vote for the election of directors are
set out below:
Nominee
|
Votes
for
|
%
for
|
Votes
withheld
|
%
withheld
|
André
Rancourt
|
42,648,175
|
99.96%
|
15,000
|
00.04%
|
Frank
Palantoni
|
42,648,175
|
99.96%
|
15,000
|
00.04%
|
Bertrand
Venne
|
42,648,175
|
99.96%
|
15,000
|
00.04%
|
Michel
Timperio
|
42,648,175
|
99.96%
|
15,000
|
00.04%
|
Louis
Doyle
|
42,648,175
|
99.96%
|
15,000
|
00.04%
|
All other matters presented for shareholder approval at the
Meeting were approved, as follows:
- Appointment of UHY McGovern Hurley LLP, Chartered Accountants,
as auditors of the Company for the coming year and authorization of
the directors to establish their remuneration;
- Amendment and ratification of the Company's existing stock
option plan; and
- Granting of stock options to purchase up to an aggregate of
3,200,000 common shares under the amended rolling option plan.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the health-care,
bio-agriculture and organic markets. The Company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty
of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include
the Company's inability to obtain sufficient financing to execute
its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise unless required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.